Drug-eluting stent for recurrent mesenteric artery in-stent restenosis

J Endovasc Ther. 2007 Oct;14(5):748-51. doi: 10.1177/152660280701400522.

Abstract

Purpose: To report the use of a drug-eluting stent (DES) for treatment of symptomatic in-stent restenosis (ISR) in the superior mesenteric artery (SMA).

Case report: A 79-year-old woman suffering from chronic renal failure and needing dialysis was admitted for vomiting, postprandial abdominal pain, and weight loss for 3 months. Computed tomographic angiography (CTA) documented massive calcification of the vascular bed, mainly in the aorta, and a very tight ostial stenosis of the SMA. A 4.5-x20-mm Genesis stent was deployed at the ostium, with good angiographic result and immediate symptomatic benefit. After 3 months, symptoms recurred; angiography demonstrated ISR. Percutaneous angioplasty with a 4-x15-mm cutting balloon was performed. The patient remained asymptomatic for only 2 months; recurrent ISR at this time was treated with a 3.5-x24-mm coronary TAXUS Express paclitaxel-eluting coronary stent deployed inside the previously implanted stent. Under prolonged double antiplatelet regimen, the patient was asymptomatic at the 8-month follow-up; CTA demonstrated patency of the SMA.

Conclusion: Considering the high rate of restenosis and the periprocedural complications described with endovascular treatment of SMA stenosis, a drug-eluting stent may be a good option not only for the treatment of restenosis but also in de novo lesions, at least when the vessel diameter is <4.5 mm.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiography, Digital Subtraction
  • Angioplasty, Balloon / instrumentation*
  • Cardiovascular Agents / administration & dosage*
  • Drug-Eluting Stents*
  • Female
  • Humans
  • Mesenteric Artery, Superior / diagnostic imaging
  • Mesenteric Vascular Occlusion / diagnostic imaging
  • Mesenteric Vascular Occlusion / physiopathology
  • Mesenteric Vascular Occlusion / therapy*
  • Paclitaxel / administration & dosage*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Secondary Prevention
  • Stents*
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vascular Patency

Substances

  • Cardiovascular Agents
  • Platelet Aggregation Inhibitors
  • Paclitaxel